HC Wainwright Reiterates Buy Rating for Benitec Biopharma (NASDAQ:BNTC)

HC Wainwright reaffirmed their buy rating on shares of Benitec Biopharma (NASDAQ:BNTC - Free Report) in a report released on Monday,Benzinga reports. The firm currently has a $28.00 target price on the biotechnology company's stock. HC Wainwright also issued estimates for Benitec Biopharma's Q4 2025 earnings at ($0.25) EPS and FY2025 earnings at ($1.33) EPS.

Separately, JMP Securities reiterated a "market outperform" rating and set a $20.00 price target on shares of Benitec Biopharma in a research note on Thursday, May 15th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $24.71.

Benitec Biopharma Stock Down 1.9%

BNTC stock traded down $0.27 during trading hours on Monday, hitting $13.66. The company's stock had a trading volume of 31,199 shares, compared to its average volume of 40,987. The stock has a 50 day moving average price of $13.62 and a two-hundred day moving average price of $12.08. Benitec Biopharma has a 12 month low of $5.74 and a 12 month high of $16.90. The company has a market capitalization of $349.70 million, a PE ratio of -9.05 and a beta of 0.34.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.12. Sell-side analysts expect that Benitec Biopharma will post -1.48 earnings per share for the current year.

Insider Buying and Selling at Benitec Biopharma

In other Benitec Biopharma news, Director Suvretta Capital Management, L purchased 900,000 shares of the business's stock in a transaction dated Wednesday, March 26th. The stock was bought at an average cost of $13.00 per share, for a total transaction of $11,700,000.00. Following the completion of the acquisition, the director now directly owns 8,793,245 shares in the company, valued at $114,312,185. This represents a 11.40% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.30% of the company's stock.

Institutional Investors Weigh In On Benitec Biopharma

Several hedge funds and other institutional investors have recently modified their holdings of BNTC. Ameriprise Financial Inc. raised its stake in Benitec Biopharma by 138.4% during the 4th quarter. Ameriprise Financial Inc. now owns 35,476 shares of the biotechnology company's stock valued at $448,000 after purchasing an additional 20,597 shares during the last quarter. 683 Capital Management LLC bought a new position in shares of Benitec Biopharma during the 4th quarter worth about $452,000. Northern Trust Corp raised its position in shares of Benitec Biopharma by 54.2% during the fourth quarter. Northern Trust Corp now owns 38,200 shares of the biotechnology company's stock valued at $482,000 after buying an additional 13,425 shares during the last quarter. Informed Momentum Co LLC bought a new stake in shares of Benitec Biopharma in the first quarter valued at about $512,000. Finally, Goldman Sachs Group Inc. bought a new stake in shares of Benitec Biopharma in the first quarter valued at about $597,000. Institutional investors and hedge funds own 52.19% of the company's stock.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.